Ingmar Wolff

Docetaxel (Taxotere) in advanced malignant melanoma: a phase II study of the EORTC early clinical trials group

Steinar Aamdal, Ingmar Wolff, Steven Kaplan et al. · European Journal of Cancer · 1994 · 82 citations

Medicine, Oncology, Pharmacology +12

Analyses of Potential Predictive Markers and Survival Data for a Response to Sunitinib in Patients with Metastatic Renal Cell Carcinoma

Juana Dornbusch, Aristeidis Zacharis, Matthias Meinhardt et al. · PLoS ONE · 2013 · 65 citations · Full text

Medicine, Oncology, Pharmacology +17

EO9 phase II study in advanced breast, gastric, pancreatic and colorectal carcinoma by the EORTC Early Clinical Studies Group

Luc Dirix, Jim Cassidy, Ron Epelbaum et al. · European Journal of Cancer · 1996 · 60 citations · Full text

Medicine, Oncology, Surgery +9

Do we need new high-risk criteria for surgically treated renal cancer patients to improve the outcome of future clinical trials in the adjuvant setting? Results of a comprehensive analysis based on the multicenter CORONA database

Ingmar Wolff, Matthias May, B. Hoschke et al. · European Journal of Surgical Oncology · 2016 · 56 citations · Full text

Medicine, Nephrology, Oncology +13

Selenoprotein P Status Correlates to Cancer-Specific Mortality in Renal Cancer Patients

Hellmuth Meyer, Tobias Endermann, Carsten Stephan et al. · PLoS ONE · 2012 · 54 citations · Full text

Medicine, Cancer Biology, Oncology +17